Hormonal
In adults with obesity without diabetes, tirzepatide produces significantly greater weight loss and cardiometabolic improvements than semaglutide over 6 months, even when semaglutide patients receive higher maintenance doses.
If you are choosing between tirzepatide and semaglutide for obesity management without diabetes, tirzepatide offers greater weight loss and better cardiometabolic improvements over 6 months. This advantage holds true even if you are on a higher maintenance dose of semaglutide than the typical tirzepatide dose. Consult your doctor to determine which medication aligns best with your health profile and insurance coverage.
Consistent with clinical trials, real-world tirzepatide treatment was associated with greater 6-month weight reduction and more frequent achievement of weight-reduction targets and improvements in select cardiometabolic parameters than semaglutide among adults with obesity without diabetes. This early emergence of tirzepatide’s comparative advantage over semaglutide was observed despite more semaglutide-treated patients receiving higher doses than tirzepatide-treated patients.
Why this rating
Large real-world retrospective cohort (n=2,396) with robust propensity-score weighting and sensitivity analyses, though observational design limits causal certainty compared to RCTs.
Source
Comparative effectiveness of tirzepatide and semaglutide for obesity management in US clinical practice: a 6-month retrospective cohort study
C Le Roux et al. · Journal of Endocrinological Investigation · 2026
DOI 10.1007/s40618-025-02792-1
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →